Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Proteomics. 2008 Dec;5(6):779-85. doi: 10.1586/14789450.5.6.779.

SELDI-TOF serum proteomics and breast cancer: which perspective?

Author information

Chemical-Clinical Microbiology and Immunology Laboratory Unit, 'Giovanni Paolo II', National Cancer Institute, Via Samuel F. Hahnemann 10, 70126 Bari, Italy.


Despite the efforts of recent years, clinicians still lack reliable biomarkers for diagnosis, prognosis and prediction of clinical outcomes in breast cancer patients. Owing to the large number of people potentially involved in the management of this clinical problem, the search for noninvasive and repeatable laboratory assays has been intensive. Recently, the proteomic profiling performed by SELDI-TOF mass spectrometry, has been proposed in order to identify new clusters of serum markers that could be potentially useful in breast cancer management. The purpose of this special report is to review the literature on SELDI-TOF technology applied on serum coming from healthy people and breast cancer patients, in order to verify the clinical applicability of such approach. We conclude that potential new biomarkers, first of all for early diagnosis of breast cancer, need to be validated in larger clinical series.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center